Uric acid and neurological disease: a narrative review
暂无分享,去创建一个
[1] Hojin Choi,et al. Prevalence of motor neuron diseases in gout patients: a nationwide population-based cohort study , 2022, Neurological Sciences.
[2] H. Jinnah,et al. Uric Acid in Parkinson′s Disease: What Is the Connection? , 2022, Movement disorders : official journal of the Movement Disorder Society.
[3] E. Mazzon,et al. Inosine in Neurodegenerative Diseases: From the Bench to the Bedside , 2022, Molecules.
[4] S. M. Kim,et al. Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone , 2022, Redox report : communications in free radical research.
[5] K. Misawa,et al. Hypouricemia and Urate Transporters , 2022, Biomedicines.
[6] Min Zhang,et al. Plasma Uric Acid Helps Predict Cognitive Impairment in Patients With Amyotrophic Lateral Sclerosis , 2021, Frontiers in Neurology.
[7] D. Mozaffarian,et al. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. , 2021, JAMA.
[8] J. Teng,et al. Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder , 2021, Journal of Neurology.
[9] R. Yin,et al. Association between uric acid and the prognosis of acute ischemic stroke: A systematic review and meta-analysis. , 2021, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[10] P. Shaw,et al. Amyotrophic lateral sclerosis alters the metabolic aging profile in patient derived fibroblasts , 2021, Neurobiology of Aging.
[11] Qi-Jie Zhang,et al. Serum Uric Acid Levels Predict Mortality Risk in Male Amyotrophic Lateral Sclerosis Patients , 2021, Frontiers in Neurology.
[12] A. Rae-Grant,et al. Diagnosis and Treatment of Multiple Sclerosis: A Review. , 2021, JAMA.
[13] Francesca N. Delling,et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. , 2021, Circulation.
[14] A. Tuttolomondo,et al. Neuroinflammatory Mechanisms in Ischemic Stroke: Focus on Cardioembolic Stroke, Background, and Therapeutic Approaches , 2020, International journal of molecular sciences.
[15] J. Jankovic,et al. Parkinson’s disease: etiopathogenesis and treatment , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[16] B. Song,et al. Serum Uric Acid Level and Multiple Sclerosis: A Mendelian Randomization Study , 2020, Frontiers in Genetics.
[17] A. Pisani,et al. Young-onset and late-onset Parkinson's disease exhibit a different profile of fluid biomarkers and clinical features , 2020, Neurobiology of Aging.
[18] M. Kanbay,et al. The causality between the serum uric acid level and stroke , 2020, Hypertension Research.
[19] K. Yamagishi,et al. Serum uric acid and risk of stroke and its types: the Circulatory Risk in Communities Study (CIRCS) , 2020, Hypertension Research.
[20] G. Sobue,et al. Prognosis of amyotrophic lateral sclerosis patients undergoing tracheostomy invasive ventilation therapy in Japan , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[21] S. Larsson. with at a Mendelian randomization study. , 2020 .
[22] N. Limdi,et al. Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study. , 2019, Hypertension.
[23] G. Feuchtner,et al. Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout. , 2019, JAMA cardiology.
[24] J. Goudreau,et al. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial , 2019, Neurology.
[25] Sebastian Heinzel,et al. Update of the MDS research criteria for prodromal Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.
[26] D. Burn,et al. Urate and Homocysteine: Predicting Motor and Cognitive Changes in Newly Diagnosed Parkinson’s Disease , 2019, Journal of Parkinson's disease.
[27] I. Hisatome,et al. Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy , 2019, European heart journal.
[28] S. Ito,et al. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[29] Albert A. Taylor,et al. Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis , 2018, Annals of clinical and translational neurology.
[30] D. Solomon,et al. Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout. , 2018, Journal of the American College of Cardiology.
[31] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[32] A. Soumaré,et al. Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study , 2017, Annals of the rheumatic diseases.
[33] 永井拓,et al. うつを予防する生活習慣に関する前向きコホート研究:Circulatory Risk in Communities Study(CIRCS) , 2018 .
[34] A. Ascherio,et al. Targeting urate to reduce oxidative stress in Parkinson disease , 2017, Experimental Neurology.
[35] Jin Xue,et al. Low uric acid is a risk factor in mild cognitive impairment , 2017, Neuropsychiatric disease and treatment.
[36] Miao Liu,et al. Relationship between serum uric acid level and mild cognitive impairment in Chinese community elderly , 2017, BMC Neurology.
[37] F. Guerrero‐Romero,et al. Serum uric acid concentrations are directly associated with the presence of benign multiple sclerosis , 2017, Neurological Sciences.
[38] Tan Xu,et al. Sex‐Specific Relationship Between Serum Uric Acid and Risk of Stroke: A Dose‐Response Meta‐Analysis of Prospective Studies , 2017, Journal of the American Heart Association.
[39] Y. Long,et al. Elevated cerebrospinal fluid uric acid during relapse of neuromyelitis optica spectrum disorders , 2016, Brain and behavior.
[40] J. Singh,et al. Allopurinol and the risk of atrial fibrillation in the elderly: a study using Medicare data , 2016, Annals of the rheumatic diseases.
[41] L. Marshall. Parkinson disease , 2017, Nature Reviews Disease Primers.
[42] A. Rodrigues,et al. Inosine, an Endogenous Purine Nucleoside, Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis: a Role for A2A Adenosine Receptor , 2017, Molecular Neurobiology.
[43] I. Kubota,et al. Associations between serum uric acid levels and the incidence of nonfatal stroke: a nationwide community-based cohort study , 2017, Clinical and Experimental Nephrology.
[44] M. Nagai,et al. Correction:Serum Uric Acid and Mortality Form Cardiovascular Disease:EPOCH-JAPAN Study , 2016, Journal of atherosclerosis and thrombosis.
[45] J. Singh,et al. Allopurinol and the risk of stroke in older adults receiving medicare , 2016, BMC Neurology.
[46] Jun Wang,et al. Low serum uric acid levels in patients with multiple sclerosis and neuromyelitis optica: An updated meta-analysis. , 2016, Multiple sclerosis and related disorders.
[47] A. Rodrigues,et al. Inosine, an Endogenous Purine Nucleoside, Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis: a Role for A2A Adenosine Receptor , 2016, Molecular Neurobiology.
[48] J. Hallas,et al. Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study. , 2016, The American journal of medicine.
[49] A. Ascherio,et al. Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.
[50] A. Dominiczak,et al. Allopurinol and Cardiovascular Outcomes in Adults With Hypertension , 2016, Hypertension.
[51] J. Hewitt,et al. Serum uric acid level and association with cognitive impairment and dementia: systematic review and meta-analysis , 2016, AGE.
[52] M. Hernán,et al. Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study , 2015, Annals of the rheumatic diseases.
[53] C. Chai,et al. Increased risk of osteoporosis in patients with erectile dysfunction , 2016, Medicine.
[54] Yangang Wang,et al. Inverse Association Between Serum Uric Acid Levels and Alzheimer’s Disease Risk , 2016, Molecular Neurobiology.
[55] Richard J. Johnson. Why focus on uric acid? , 2015, Current medical research and opinion.
[56] A. Traboulsee,et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.
[57] M. Arias Gómez,et al. Associated Inosine to interferon: results of a clinical trial in multiple sclerosis , 2015, Acta neurologica Scandinavica.
[58] V. Morra,et al. Uric acid: a potential biomarker of multiple sclerosis and of its disability , 2015, Clinical chemistry and laboratory medicine.
[59] C. Russo,et al. Uric acid in relapsing–remitting multiple sclerosis: a 2-year longitudinal study , 2015, Journal of Neurology.
[60] M. T. Pellecchia,et al. Uric acid relates to dopamine transporter availability in Parkinson's disease , 2015, Acta neurologica Scandinavica.
[61] M. T. Pellecchia,et al. Presence and progression of non‐motor symptoms in relation to uric acid in de novo Parkinson's disease , 2015, European journal of neurology.
[62] Yun-Jiu Cheng,et al. Risk of Thromboembolic Events in Atrial Fibrillation With Chronic Kidney Disease , 2015, Stroke.
[63] Cheng-Li Lin,et al. A population-based cohort study. , 2015 .
[64] M. Biddle,et al. A report from the American Heart Association Council on Cardiovascular and Stroke Nursing. , 2015, The Journal of cardiovascular nursing.
[65] M. Roudier,et al. Prevalence of birefringent crystals in cardiac and prostatic tissues, an observational study , 2014, BMJ Open.
[66] Min Li,et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis of prospective studies. , 2014, Atherosclerosis.
[67] E. Sharifipour,et al. Allopurinol as a Preventive Contrivance after Acute Ischemic Stroke in Patients with a High Level of Serum Uric Acid: A Randomized, Controlled Trial , 2013, Medical Principles and Practice.
[68] L. Cui,et al. Serum uric acid levels and their correlation with clinical and cerebrospinal fluid parameters in patients with neuromyelitis optica , 2013, Journal of Clinical Neuroscience.
[69] Hsin-Chieh Yeh,et al. Effect of the 2011 vs 2003 duty hour regulation-compliant models on sleep duration, trainee education, and continuity of patient care among internal medicine house staff: a randomized trial. , 2013, JAMA internal medicine.
[70] A. Vincent,et al. Reduced serum uric acid levels in neuromyelitis optica: serum uric acid levels are reduced during relapses in NMO , 2012, Acta neurologica Scandinavica.
[71] A. Michotte,et al. Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon β in relapsing- remitting Multiple Sclerosis (ASIIMS) trial , 2010, Multiple sclerosis.
[72] C. Tanner,et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. , 2009, Archives of neurology.
[73] Hyon K. Choi,et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. , 2009, Arthritis and rheumatism.
[74] T. Whitmarsh. The treatment of multiple sclerosis with inosine. , 2009, Journal of Alternative and Complementary Medicine.
[75] R. Castro,et al. Serum homocysteine: interplay with other circulating and genetic factors in association to Alzheimer's type dementia. , 2009, Clinical biochemistry.
[76] S. Karumanchi,et al. Reactions of Peroxynitrite with Uric Acid: Formation of Reactive Intermediates, Alkylated Products and Triuret, and In Vivo Production of Triuret Under Conditions of Oxidative Stress , 2009, Nucleosides, nucleotides & nucleic acids.
[77] A. Hofman,et al. Serum uric acid and cognitive function and dementia. , 2008, Brain : a journal of neurology.
[78] A. Lang,et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. , 2008, Archives of neurology.
[79] M. Weisskopf,et al. Plasma urate and risk of Parkinson's disease. , 2007, American journal of epidemiology.
[80] T. Nakagawa,et al. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. , 2007, American journal of physiology. Cell physiology.
[81] G. Toncev. Therapeutic value of serum uric acid levels increasing in the treatment of multiple sclerosis. , 2006, Vojnosanitetski pregled.
[82] F. Martinon,et al. Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.
[83] K. Leung,et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[84] A. Sanabria,et al. Randomized controlled trial. , 2005, World journal of surgery.
[85] G. Aldini,et al. Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. , 2004, Archives of biochemistry and biophysics.
[86] Y. Moriwaki,et al. Effect of inosine on the plasma concentration of uridine and purine bases. , 2002, Metabolism: clinical and experimental.
[87] H. Koprowski,et al. Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease , 2001, Multiple sclerosis.
[88] T. Panetta,et al. Identification of uric acid and xanthine oxidase in atherosclerotic plaque. , 2001, The American journal of cardiology.
[89] J. Marinković,et al. Uric acid levels in sera from patients with multiple sclerosis , 2001, Journal of Neurology.
[90] F Santeusanio,et al. Relation Between Serum Uric Acid and Risk of Cardiovascular Disease in Essential Hypertension: The PIUMA Study , 2000, Hypertension.
[91] D. Inzitari,et al. Parkinson’s disease and parkinsonism in a longitudinal study , 2000, Neurology.
[92] Robert C. Wolpert,et al. A Review of the , 1985 .